MARK BILODEAU, Ph.D.
CHIEF SCIENCE OFFICER
Mark Bilodeau is Executive Chief Scientific Officer at Tarveda, with more than 20 years of experience in medicinal chemistry and drug discovery. Previously, he was Senior Director of Medicinal Chemistry at Merck & Co. Inc., where he developed a broad background in drug discovery for the oncology, pain, neuroscience, ophthalmology, and cardiovascular therapeutic areas. While at Merck, Dr. Bilodeau was an inventor and team leader on seven molecules that advanced into clinical testing and also led a development team that brought one molecule from discovery through Phase I clinical testing. Dr. Bilodeau received a B.S. in Chemistry from Boston College and a Ph.D. in Organic Chemistry from Harvard University. He conducted postdoctoral studies at the Memorial Sloan-Kettering Cancer Center.